NewsBenzingaMorgan Stanley mantiene il giudizio "Overweight" su Gilead Sciences e alza il prezzo obiettivo a 183 dollari Morgan Stanley mantiene il giudizio "Overweight" su Gilead Sciences e alza il prezzo obiettivo a 183 dollari Benzinga 2026.10.30 18:06 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3